OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Talley on the CAPTIVATE Trial in CLL

July 10th 2018

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses the CAPTIVATE trial in patients with chronic lymphocytic leukemia (CLL).

Dr. Link on Nelarabine in Newly Diagnosed T-Cell Malignancies

July 10th 2018

Michael Link, MD, Lydia J. Lee Professor in Pediatric Cancer, professor, Pediatrics, Stanford Cancer Institute, and a 2018 Giant of Cancer Care in Pediatric Oncology, discusses the randomized trial testing nelarabine in patients with T-cell malignancies.

Dr. Esteva on the Impact of the Trastuzumab Biosimilar Approval

July 7th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses the impact of the approval of the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst).

Dr. Grivas on Ongoing Trials in Advanced Bladder Cancer

July 7th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses ongoing trials in advanced bladder cancer.

Dr. Liu on Potentially Promising Combinations in ALK-Positive NSCLC

July 7th 2018

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses potentially promising combinations in ALK-positive non–small cell lung cancer (NSCLC).

Dr. Richardson on the Synergy Between Immunomodulators and Proteasome Inhibitors

July 6th 2018

Paul Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the synergy between immunomodulators and proteasome inhibitors in the treatment of patients with relapsed/refractory multiple myeloma (RRMM).

Dr. Upadhyaya on Radiation Therapy for Young Children with Ependymoma

July 6th 2018

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses radiation therapy for young children under the age of 3 who have ependymoma.

Dr. Kosteva on Single-Agent Versus Combination Immunotherapy in NSCLC

July 5th 2018

John A. Kosteva, MD, clinical assistant professor of medicine, University of Pennsylvania School of Medicine, Abramson Cancer Center, discusses the adoption of immunotherapy into the treatment paradigm for patients with non–small cell lung cancer (NSCLC).

Dr. Stilwill on Adjuvant Advances in Melanoma

July 5th 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses adjuvant advances in the treatment of patients with melanoma.

Dr. Kwa on the TAILORx Trial in Breast Cancer

July 5th 2018

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the results of the TAILORx trial in breast cancer.

Dr. Bauman on Treatments for Patients With BRAF-Mutant NSCLC

July 4th 2018

Jessica Bauman, MD, assistant professor, Department of Hematology/Oncology, associate program director, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, discusses treatments for patients with BRAF-mutant non–small cell lung cancer (NSCLC).

Dr. Barr on Systemic Therapies for Patients With Neuroendocrine Tumors

July 4th 2018

Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses systemic therapies for patients with neuroendocrine tumors (NETs).

Dr. Levy on the Application of Liquid Biopsies in NSCLC

July 4th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the application of liquid biopsies in non–small-cell lung cancer (NSCLC).

Dr. Esteva Discusses Neratinib Updates in HER2+ Breast Cancer

July 4th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses updated neratinib (Nerlynx) data in patients with HER2-positive breast cancer.

Dr. Maughan on Enzalutamide Plus Radium-223 in mCRPC

July 4th 2018

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses enzalutamide (Xtandi) plus radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Dr. Choueiri Discusses Checkpoint Inhibitors in RCC

July 4th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).

Dr. El-Deiry on Liquid Vs Tissue Biopsies

July 3rd 2018

Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses the advantages of liquid biopsies over tissue biopsies.

Dr. Humphrey on Mogamulizumab for Cutaneous T-Cell Lymphoma

July 3rd 2018

Jeffrey Humphrey, MD, president, Kyowa Hakko Kirin Pharma, Inc., discusses the benefits of mogamulizumab for the treatment of cutaneous T-cell lymphoma.

Dr. Yardley on the Role of Biosimilars in Breast Cancer

July 3rd 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the role of biosimilars in the treatment of patients with breast cancer.

Dr. Rini on the Tolerability of Atezolizumab Plus Bevacizumab in RCC

July 3rd 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the tolerability of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.